Generally, a “Strong Buy” rating on Wall Street indicates that analysts believe the stock will appreciate and outperform the ...

Author:  Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes, UCB | Hear from UCB’s Brad Chapman on the importance of inclusion, representation, and understanding in epilepsy and rare syndromes ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...

NICE has approved another epilepsy treatment for Lennox–Gastaut syndrome. Fenfluramine can be used as an add-on to other ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

Hundreds of children with severe epilepsy will be able to benefit from a groundbreaking new treatment on the NHS that could significantly reduce their seizures, providing new hope for them and their ...

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...